JP2005503756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503756A5 JP2005503756A5 JP2002555211A JP2002555211A JP2005503756A5 JP 2005503756 A5 JP2005503756 A5 JP 2005503756A5 JP 2002555211 A JP2002555211 A JP 2002555211A JP 2002555211 A JP2002555211 A JP 2002555211A JP 2005503756 A5 JP2005503756 A5 JP 2005503756A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binding
- cells
- antibodies
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 description 675
- 108090001123 antibodies Proteins 0.000 description 675
- 230000027455 binding Effects 0.000 description 588
- 239000000427 antigen Substances 0.000 description 247
- 108091007172 antigens Proteins 0.000 description 246
- 102000038129 antigens Human genes 0.000 description 246
- 210000004027 cells Anatomy 0.000 description 230
- 239000003814 drug Substances 0.000 description 181
- 210000001772 Blood Platelets Anatomy 0.000 description 129
- 235000001014 amino acid Nutrition 0.000 description 93
- 229940079593 drugs Drugs 0.000 description 90
- 150000001413 amino acids Chemical class 0.000 description 86
- 230000002401 inhibitory effect Effects 0.000 description 83
- 206010024324 Leukaemias Diseases 0.000 description 71
- 239000008194 pharmaceutical composition Substances 0.000 description 66
- 239000003795 chemical substances by application Substances 0.000 description 63
- 102100014586 SELPLG Human genes 0.000 description 57
- 241000282414 Homo sapiens Species 0.000 description 54
- 229920001184 polypeptide Polymers 0.000 description 51
- 210000004881 tumor cells Anatomy 0.000 description 50
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 46
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 46
- 125000003275 alpha amino acid group Chemical group 0.000 description 45
- 235000002374 tyrosine Nutrition 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 229960004441 Tyrosine Drugs 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 42
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 41
- 239000011159 matrix material Substances 0.000 description 41
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 38
- 238000004220 aggregation Methods 0.000 description 36
- 230000002776 aggregation Effects 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- 102400000446 Glycocalicin Human genes 0.000 description 32
- 101800001015 Glycocalicin Proteins 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 32
- -1 acetyl salicylic Chemical compound 0.000 description 32
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 31
- 201000010099 disease Diseases 0.000 description 31
- 108010045030 monoclonal antibodies Proteins 0.000 description 31
- 102000005614 monoclonal antibodies Human genes 0.000 description 31
- 230000001603 reducing Effects 0.000 description 31
- 229960005261 Aspartic Acid Drugs 0.000 description 29
- 235000003704 aspartic acid Nutrition 0.000 description 29
- 238000005096 rolling process Methods 0.000 description 29
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 28
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 28
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 28
- 206010027476 Metastasis Diseases 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 27
- 229960002449 Glycine Drugs 0.000 description 26
- 239000004471 Glycine Substances 0.000 description 26
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 25
- 101700027814 CDR3 Proteins 0.000 description 24
- 229960002989 Glutamic Acid Drugs 0.000 description 24
- 239000005092 Ruthenium Substances 0.000 description 24
- 235000013922 glutamic acid Nutrition 0.000 description 24
- 239000004220 glutamic acid Substances 0.000 description 24
- 229910052740 iodine Inorganic materials 0.000 description 24
- 239000011630 iodine Substances 0.000 description 24
- 239000000863 peptide conjugate Substances 0.000 description 24
- 229910052707 ruthenium Inorganic materials 0.000 description 24
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 23
- 239000003146 anticoagulant agent Substances 0.000 description 23
- 239000000562 conjugate Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 206010035226 Plasma cell myeloma Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000002285 radioactive Effects 0.000 description 22
- 229960001153 serine Drugs 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 21
- 208000007536 Thrombosis Diseases 0.000 description 21
- 239000002246 antineoplastic agent Substances 0.000 description 21
- 108010063101 fibrinogen gamma' Proteins 0.000 description 21
- 229920000669 heparin Polymers 0.000 description 21
- 230000004054 inflammatory process Effects 0.000 description 21
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 21
- 206010022114 Injury Diseases 0.000 description 20
- 239000000063 antileukemic agent Substances 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 200000000008 restenosis Diseases 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 206010061289 Metastatic neoplasm Diseases 0.000 description 19
- 230000002159 abnormal effect Effects 0.000 description 19
- 230000002708 enhancing Effects 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 230000003993 interaction Effects 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 230000001394 metastastic Effects 0.000 description 19
- 229950004257 Ristocetin Drugs 0.000 description 18
- 108010081391 Ristocetin Proteins 0.000 description 18
- 229910052775 Thulium Inorganic materials 0.000 description 18
- 201000009251 multiple myeloma Diseases 0.000 description 18
- 229910052702 rhenium Inorganic materials 0.000 description 18
- VUOPFFVAZTUEGW-FBMDODLCSA-N ristocetin Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](COC5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-FBMDODLCSA-N 0.000 description 18
- 229910052714 tellurium Inorganic materials 0.000 description 18
- 210000000265 Leukocytes Anatomy 0.000 description 17
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 229960000975 Daunorubicin Drugs 0.000 description 16
- 229960004679 Doxorubicin Drugs 0.000 description 16
- 229960002897 Heparin Drugs 0.000 description 16
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 16
- 239000000969 carrier Substances 0.000 description 16
- 230000000295 complement Effects 0.000 description 16
- 239000000539 dimer Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000002823 phage display Methods 0.000 description 16
- 238000005670 sulfation reaction Methods 0.000 description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 15
- 210000004369 Blood Anatomy 0.000 description 15
- 102000003886 Glycoproteins Human genes 0.000 description 15
- 108090000288 Glycoproteins Proteins 0.000 description 15
- 231100000765 Toxin Toxicity 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 230000000181 anti-adherence Effects 0.000 description 15
- 239000002260 anti-inflammatory agent Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 230000001965 increased Effects 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 108020003112 toxins Proteins 0.000 description 15
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 108010035766 P-Selectin Proteins 0.000 description 14
- 102100003519 SELP Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000000840 anti-viral Effects 0.000 description 14
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- 229960004397 Cyclophosphamide Drugs 0.000 description 13
- 229960000310 ISOLEUCINE Drugs 0.000 description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 13
- 229960005190 Phenylalanine Drugs 0.000 description 13
- 229960002429 Proline Drugs 0.000 description 13
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 13
- 235000014633 carbohydrates Nutrition 0.000 description 13
- 229960003136 leucine Drugs 0.000 description 13
- 229960000060 monoclonal antibodies Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- OHJKXVLJWUPWQG-IUYNYSEKSA-J (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate Chemical compound O[C@@H]1C(NS([O-])(=O)=O)C(O)O[C@H](COS([O-])(=O)=O)C1O[C@H]1C(OS([O-])(=O)=O)[C@@H](O)C(O)C(C([O-])=O)O1 OHJKXVLJWUPWQG-IUYNYSEKSA-J 0.000 description 12
- 230000002378 acidificating Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000000875 corresponding Effects 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 229910052733 gallium Inorganic materials 0.000 description 12
- 229910052738 indium Inorganic materials 0.000 description 12
- 229910052753 mercury Inorganic materials 0.000 description 12
- 206010003816 Autoimmune disease Diseases 0.000 description 11
- 229940012952 Fibrinogen Drugs 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 11
- 102000008946 Fibrinogen Human genes 0.000 description 11
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
- 210000004898 N-terminal fragment Anatomy 0.000 description 11
- 239000004473 Threonine Substances 0.000 description 11
- 102100019017 VWF Human genes 0.000 description 11
- 229960002898 threonine Drugs 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 108010047303 von Willebrand Factor Proteins 0.000 description 11
- 229960001134 von Willebrand factor Drugs 0.000 description 11
- 102100012771 LUM Human genes 0.000 description 10
- 108010076371 Lumican Proteins 0.000 description 10
- 230000021164 cell adhesion Effects 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 9
- 229960001230 Asparagine Drugs 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 9
- 102100015239 F2 Human genes 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- 108090001030 Lipoproteins Proteins 0.000 description 9
- 102000004895 Lipoproteins Human genes 0.000 description 9
- 229940039716 Prothrombin Drugs 0.000 description 9
- 108010094028 Prothrombin Proteins 0.000 description 9
- 235000009582 asparagine Nutrition 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 108091008117 polyclonal antibodies Proteins 0.000 description 9
- 101700015794 pro Proteins 0.000 description 9
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 8
- 229940023040 Acyclovir Drugs 0.000 description 8
- 229960002963 Ganciclovir Drugs 0.000 description 8
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 8
- 101710044247 ITGA2B Proteins 0.000 description 8
- 102100019332 ITGA2B Human genes 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000002381 Plasma Anatomy 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 229960002555 Zidovudine Drugs 0.000 description 8
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 8
- 229960004150 aciclovir Drugs 0.000 description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 8
- 239000002257 antimetastatic agent Substances 0.000 description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 8
- 229920001600 hydrophobic polymer Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000001717 pathogenic Effects 0.000 description 8
- 230000001568 sexual Effects 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- HEFNNWSXXWATRW-JTQLQIEISA-N (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 7
- OJZYRQPMEIEQFC-UAWLTFRCSA-N (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 description 7
- MUXFZBHBYYYLTH-UHFFFAOYSA-N 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 7
- VXMGUKIFTVZUCT-UHFFFAOYSA-N 2-chloro-2H-chromene Chemical compound C1=CC=C2C=CC(Cl)OC2=C1 VXMGUKIFTVZUCT-UHFFFAOYSA-N 0.000 description 7
- 229940009456 Adriamycin Drugs 0.000 description 7
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 7
- 108090000617 Cathepsin G Proteins 0.000 description 7
- 102000004173 Cathepsin G Human genes 0.000 description 7
- RRGUKTPIGVIEKM-UHFFFAOYSA-N Cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 7
- 229940018872 Dalteparin Sodium Drugs 0.000 description 7
- OEHFRZLKGRKFAS-UHFFFAOYSA-N Droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 7
- 210000002889 Endothelial Cells Anatomy 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 229960000905 Indomethacin Drugs 0.000 description 7
- 102000016551 L-Selectin Human genes 0.000 description 7
- 108010092694 L-Selectin Proteins 0.000 description 7
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 7
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 7
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 7
- 210000004940 Nucleus Anatomy 0.000 description 7
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 7
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 7
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 7
- 229960000894 Sulindac Drugs 0.000 description 7
- 229950004227 Zaltoprofen Drugs 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 230000000844 anti-bacterial Effects 0.000 description 7
- 229940121363 anti-inflammatory agents Drugs 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 7
- 229960004588 cilostazol Drugs 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 229960004120 defibrotide Drugs 0.000 description 7
- 229960002923 denileukin diftitox Drugs 0.000 description 7
- 108010017271 denileukin diftitox Proteins 0.000 description 7
- 230000001419 dependent Effects 0.000 description 7
- 229960003428 dexibuprofen Drugs 0.000 description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 7
- 229960001259 diclofenac Drugs 0.000 description 7
- 229960001850 droxicam Drugs 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 7
- 229960000681 leflunomide Drugs 0.000 description 7
- 229950009365 limaprost Drugs 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000003211 malignant Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 229960002009 naproxen Drugs 0.000 description 7
- 229960000965 nimesulide Drugs 0.000 description 7
- 238000004091 panning Methods 0.000 description 7
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 229960003101 pranoprofen Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960000371 rofecoxib Drugs 0.000 description 7
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- UHBYWPGGCSDKFX-VKHMYHEASA-N γ-carboxy-L-glutamic acid zwitterion Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 7
- 210000003719 B-Lymphocytes Anatomy 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 6
- 229960001561 Bleomycin Drugs 0.000 description 6
- 210000004204 Blood Vessels Anatomy 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 210000004900 C-terminal fragment Anatomy 0.000 description 6
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
- 229960004630 Chlorambucil Drugs 0.000 description 6
- 229960000684 Cytarabine Drugs 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 6
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 6
- 229960000908 Idarubicin Drugs 0.000 description 6
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 6
- 102000018358 Immunoglobulins Human genes 0.000 description 6
- 108060003951 Immunoglobulins Proteins 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 210000001616 Monocytes Anatomy 0.000 description 6
- 210000000440 Neutrophils Anatomy 0.000 description 6
- 229960001592 Paclitaxel Drugs 0.000 description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 6
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 6
- 229960003433 Thalidomide Drugs 0.000 description 6
- 229960004528 Vincristine Drugs 0.000 description 6
- 229940053819 WinRho Drugs 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 6
- 230000002769 anti-restenotic Effects 0.000 description 6
- 229910052797 bismuth Inorganic materials 0.000 description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229960000590 celecoxib Drugs 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 150000002019 disulfides Chemical class 0.000 description 6
- 229960000390 fludarabine Drugs 0.000 description 6
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 229960001330 hydroxycarbamide Drugs 0.000 description 6
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 6
- 229940027318 hydroxyurea Drugs 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910052743 krypton Inorganic materials 0.000 description 6
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 6
- 229960004618 prednisone Drugs 0.000 description 6
- 229930003347 taxol Natural products 0.000 description 6
- 229910052713 technetium Inorganic materials 0.000 description 6
- 229960004964 temozolomide Drugs 0.000 description 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
- 229910052724 xenon Inorganic materials 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 231100000776 Exotoxin Toxicity 0.000 description 5
- 229940049906 Glutamate Drugs 0.000 description 5
- 102000004851 Immunoglobulin G Human genes 0.000 description 5
- 108090001095 Immunoglobulin G Proteins 0.000 description 5
- 101700037498 PE38 Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 5
- 229940000204 Reviparin sodium Drugs 0.000 description 5
- 108010039491 Ricin Proteins 0.000 description 5
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 5
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 108091006028 chimera Proteins 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 239000002095 exotoxin Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 208000008787 Cardiovascular Disease Diseases 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 206010028549 Myeloid leukaemia Diseases 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 102000003800 Selectins Human genes 0.000 description 4
- 108090000184 Selectins Proteins 0.000 description 4
- 208000010019 Vascular System Injury Diseases 0.000 description 4
- 206010027701 Vascular injury Diseases 0.000 description 4
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 200000000002 platelet activation Diseases 0.000 description 4
- 230000036647 reaction Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- 229950003499 FIBRIN Drugs 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102100003517 GP1BA Human genes 0.000 description 3
- 101700034668 GP1BA Proteins 0.000 description 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 210000003593 Megakaryocytes Anatomy 0.000 description 3
- 208000010125 Myocardial Infarction Diseases 0.000 description 3
- 206010025310 Other lymphomas Diseases 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 208000007541 Preleukemia Diseases 0.000 description 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 3
- 102100003520 SELE Human genes 0.000 description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000719 anti-leukaemic Effects 0.000 description 3
- 230000002001 anti-metastasis Effects 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229940106780 human fibrinogen Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 125000000012 isoleucine group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000001235 proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000011056 retinal disease Diseases 0.000 description 3
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 2
- 206010060965 Arterial stenosis Diseases 0.000 description 2
- 210000000649 B-Lymphocyte Subsets Anatomy 0.000 description 2
- 101710010421 BN863_22020 Proteins 0.000 description 2
- 101710010411 BN863_22030 Proteins 0.000 description 2
- 210000000601 Blood Cells Anatomy 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 102100013472 CCK Human genes 0.000 description 2
- 108010048926 Cholecystokinin Proteins 0.000 description 2
- 229940107137 Cholecystokinin Drugs 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 230000036826 Excretion Effects 0.000 description 2
- 108090000270 Ficain Proteins 0.000 description 2
- POTUGHMKJGOKRI-UHFFFAOYSA-N Ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 2
- 210000003714 Granulocytes Anatomy 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 210000002500 Microbodies Anatomy 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 230000002744 anti-aggregatory Effects 0.000 description 2
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000000536 complexating Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001461 cytolytic Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 235000019836 ficin Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000002318 immunoblotting Methods 0.000 description 2
- 230000000984 immunochemical Effects 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000019635 protein sulfation Effects 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical class C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 229960004676 ANTITHROMBOTIC AGENTS Drugs 0.000 description 1
- 101710006703 AS Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101710010420 BN863_22010 Proteins 0.000 description 1
- 101710010422 BN863_22070 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000004899 C-terminal region Anatomy 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 101710017682 CPF_0221 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N Carboxyglutamic acid Chemical group OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 210000000416 Exudates and Transudates Anatomy 0.000 description 1
- 102100009013 FGG Human genes 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102100004438 GP9 Human genes 0.000 description 1
- 101700055186 GP9 Proteins 0.000 description 1
- 108020005128 Glycosidases Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 210000000224 Granular leucocyte Anatomy 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229960004198 Guanidine Drugs 0.000 description 1
- 101710007376 H1-1 Proteins 0.000 description 1
- 206010061992 Haemophilia Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101710017533 His1:CG33831 Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 210000003000 Inclusion Bodies Anatomy 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 210000004897 N-terminal region Anatomy 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 108010054395 P-selectin ligand protein Proteins 0.000 description 1
- 102100001381 PLA2G1B Human genes 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101000184883 SERPIND1 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100008471 THBD Human genes 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 108010048325 fibrinopeptides gamma Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 102000035362 glycosylated proteins Human genes 0.000 description 1
- 108091005600 glycosylated proteins Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 230000002439 hemostatic Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000022085 human SERPIND1 protein Human genes 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002998 immunogenetic Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- QGVLYPPODPLXMB-UBTYZVCOSA-N phorbol derivatives Chemical class [H][C@@]12C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@]3([H])[C@@]1(O)[C@H](C)[C@@H](O)[C@]1(O)[C@@]2([H])C1(C)C QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001180 sulfating Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25894800P | 2000-12-29 | 2000-12-29 | |
| US75118100A | 2000-12-29 | 2000-12-29 | |
| PCT/US2001/049442 WO2002053700A2 (fr) | 2000-12-29 | 2001-12-31 | Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503756A JP2005503756A (ja) | 2005-02-10 |
| JP2005503756A5 true JP2005503756A5 (fr) | 2005-06-09 |
Family
ID=26946974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555211A Pending JP2005503756A (ja) | 2000-12-29 | 2001-12-31 | 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1406930A4 (fr) |
| JP (1) | JP2005503756A (fr) |
| KR (1) | KR20030091953A (fr) |
| CN (1) | CN100347194C (fr) |
| BR (1) | BR0116764A (fr) |
| CA (1) | CA2433225A1 (fr) |
| CZ (1) | CZ20031982A3 (fr) |
| HU (1) | HUP0700079A2 (fr) |
| IL (1) | IL156689A0 (fr) |
| MX (1) | MXPA03005945A (fr) |
| PL (1) | PL366223A1 (fr) |
| RU (1) | RU2003123101A (fr) |
| WO (1) | WO2002053700A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| CN1678348A (zh) * | 2002-07-01 | 2005-10-05 | 萨文特医药公司 | 用于治疗性治疗的组合物和方法 |
| RU2006102571A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Специфические антитела человека |
| CA2536644A1 (fr) * | 2003-06-30 | 2005-02-03 | Bio-Technology General (Israel) Ltd. | Anticorps et utilisations de ceux-ci |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| AR048840A1 (es) * | 2004-05-11 | 2006-05-31 | Boehringer Ingelheim Int | Epitopes inductores de la muerte de las celulas t |
| ES2694239T3 (es) | 2010-11-12 | 2018-12-19 | Gentium S.R.L. | Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD) |
| CA2838952C (fr) | 2011-06-13 | 2020-11-24 | Stefan Bassarab | Anticorps anti-psgl-1 et leurs utilisations |
| CA2874960C (fr) | 2012-06-22 | 2021-05-18 | Gentium S.P.A. | Procede a base d'euglobuline pour la determination de l'activite biologique de defibrotide |
| WO2016013828A1 (fr) * | 2014-07-21 | 2016-01-28 | 연세대학교 산학협력단 | Mutant de domaine extracellulaire 1 de récepteur de chimiokines duffy sulfaté et utilisation associée |
| EP3026122A1 (fr) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Procédé à base cellulaire pour déterminer la puissance de défibrotide |
| JP2019031486A (ja) * | 2017-08-04 | 2019-02-28 | 公立大学法人福島県立医科大学 | 新規ポリペプチド及びその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3326693A (en) * | 1991-12-12 | 1993-07-19 | Scripps Research Institute, The | Bifunctional antithrombotic molecules and antithrombotic polypeptides |
| EP0833650A4 (fr) * | 1995-06-14 | 2005-01-19 | Gen Hospital Corp | Ligands de p-selectine et procedes et molecules associes--- |
| JPH11510543A (ja) * | 1995-08-03 | 1999-09-14 | ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ | ペプチド及びセレクチン介在炎症のｏ−グリカン阻害剤 |
| US5985833A (en) * | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
| WO1999065712A2 (fr) * | 1998-06-16 | 1999-12-23 | The Board Of Regents Of The University Of Oklahoma | Glycosulfopeptide, technique de synthese et utilisation |
-
2001
- 2001-12-31 CZ CZ20031982A patent/CZ20031982A3/cs unknown
- 2001-12-31 KR KR10-2003-7008890A patent/KR20030091953A/ko not_active Application Discontinuation
- 2001-12-31 BR BRPI0116764-2A patent/BR0116764A/pt not_active IP Right Cessation
- 2001-12-31 JP JP2002555211A patent/JP2005503756A/ja active Pending
- 2001-12-31 HU HU0700079A patent/HUP0700079A2/hu unknown
- 2001-12-31 CN CNB018228844A patent/CN100347194C/zh not_active Expired - Fee Related
- 2001-12-31 MX MXPA03005945A patent/MXPA03005945A/es not_active Application Discontinuation
- 2001-12-31 EP EP01994330A patent/EP1406930A4/fr not_active Withdrawn
- 2001-12-31 PL PL01366223A patent/PL366223A1/xx unknown
- 2001-12-31 RU RU2003123101/13A patent/RU2003123101A/ru not_active Application Discontinuation
- 2001-12-31 WO PCT/US2001/049442 patent/WO2002053700A2/fr active Application Filing
- 2001-12-31 CA CA002433225A patent/CA2433225A1/fr not_active Abandoned
- 2001-12-31 IL IL15668901A patent/IL156689A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040002450A1 (en) | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| US20090220486A1 (en) | Antibodies and uses thereof | |
| US20040001822A1 (en) | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| US20070149768A1 (en) | Specific human antibodies for selective cancer therapy | |
| US20040001839A1 (en) | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| JP2005503756A5 (fr) | ||
| JP2005503756A (ja) | 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用 | |
| AU2002246737B2 (en) | Specific human antibodies for selective cancer therapy | |
| AU2002246737A1 (en) | Specific human antibodies for selective cancer therapy | |
| US20040202665A1 (en) | Compositions and methods for therapeutic treatment | |
| JP2005536199A (ja) | 抗体及びそれらの使用 | |
| US20080274100A1 (en) | Antibodies and uses thereof | |
| EP1649001A2 (fr) | Anticorps et utilisations de ceux-ci | |
| WO2004002528A9 (fr) | Compositions et procedes pour traitement therapeutique | |
| US20040208877A1 (en) | Antibodies and uses thereof | |
| AU2002246738A1 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |